KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Deferred Taxes (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Deferred Taxes data on record, last reported at $54.4 million in Q4 2025.

  • For Q4 2025, Deferred Taxes fell 44.77% year-over-year to $54.4 million; the TTM value through Dec 2025 reached $117.6 million, down 63.64%, while the annual FY2025 figure was $117.6 million, 63.64% down from the prior year.
  • Deferred Taxes reached $54.4 million in Q4 2025 per EW's latest filing, up from $18.0 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $123.0 million in Q3 2024 and bottomed at -$10.8 million in Q1 2021.
  • Average Deferred Taxes over 5 years is $50.4 million, with a median of $49.0 million recorded in 2022.
  • Peak YoY movement for Deferred Taxes: crashed 200.0% in 2021, then soared 1287.18% in 2022.
  • A 5-year view of Deferred Taxes shows it stood at $61.5 million in 2021, then soared by 72.03% to $105.8 million in 2022, then fell by 13.61% to $91.4 million in 2023, then rose by 7.77% to $98.5 million in 2024, then plummeted by 44.77% to $54.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $54.4 million in Q4 2025, $18.0 million in Q3 2025, and $20.9 million in Q2 2025.